Video

Dr. Brugarolas on rationale for targeting HIF2α in renal cell carcinoma

“One of the processes that is regulated by HIF2α is angiogenesis,” says James Brugarolas, MD, PhD.

James Brugarolas, MD, PhD, director of the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses the rationale for developing therapies for renal cell carcinoma that target HIF2α.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Betty Wang, MD, discusses studies from the 2025 EAU meeting
© 2025 MJH Life Sciences

All rights reserved.